Jacobs Levy Equity Management Inc. Buys New Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Jacobs Levy Equity Management Inc. bought a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 139,854 shares of the company's stock, valued at approximately $607,000. Jacobs Levy Equity Management Inc. owned approximately 0.27% of Cardiff Oncology as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Cardiff Oncology by 68.7% in the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock valued at $1,253,000 after buying an additional 117,514 shares in the last quarter. HB Wealth Management LLC acquired a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $105,000. American Century Companies Inc. grew its stake in shares of Cardiff Oncology by 12.8% in the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after buying an additional 6,140 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Cardiff Oncology by 24.0% in the fourth quarter. Rhumbline Advisers now owns 53,172 shares of the company's stock valued at $231,000 after buying an additional 10,290 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company's stock valued at $141,000 after buying an additional 39,542 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Stock Up 5.2%

NASDAQ:CRDF traded up $0.15 during trading hours on Friday, reaching $3.03. 1,306,373 shares of the stock were exchanged, compared to its average volume of 1,133,257. The firm has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $3.45. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $5.64. The stock has a market capitalization of $201.57 million, a P/E ratio of -3.22 and a beta of 1.81.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. As a group, analysts expect that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday, May 9th.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.